Totifen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Totifen

What is Totifen? (Overview)

Property Description
Active Ingredient Ketotifen Fumarate (Ketotifen)
Forms Oral (Syrup, Tablets) and Ophthalmic Solution (Eye drops)
Pharmacological Class Histamine H1-receptor Antagonist and Mast Cell Stabilizer
Common Purpose Management of allergic symptoms and allergic inflammation
Origin Synthetic compound

What is the Composition and Class of Totifen?

Totifen is a medicinal entity whose active component is Ketotifen Fumarate (INN), a synthetic compound with a chemically distinct benzocycloheptathiophene structure. The drug is classified as a dual-action agent, functioning as both a Histamine H1-receptor Antagonist and a Mast Cell Stabilizer. This dual pharmacological classification is the foundation of its activity and is recognized for its role in modulating the allergic response.

Ketotifen selectively blocks histamine (H1) receptors and interferes with the release of inflammatory mediators from mast cells involved in hypersensitivity reactions. By this mechanism, the medicine helps manage allergic discomfort by addressing the immediate effects of histamine and the cellular processes associated with inflammation.


Available Forms and General Purpose of the Medicine

Totifen is manufactured in multiple dosage forms, facilitating both systemic and topical administration. These include oral forms, such as syrup and tablets, and sterile ophthalmic solutions (eye drops).

The general purpose of this dual-action agent is to provide control over allergic inflammation. This preventive action, derived from its mast cell stabilizing property, means the drug offers sustained anti-allergic support alongside the relief of symptoms and is designed to modulate the body’s overall allergic response.

Regulatory References

  1. systemic
  2. topical administration
  3. sterile ophthalmic solutions (eye drops)
  4. MedlinePlus

What side effects are possible with Totifen?

Possible Side Effects and Safety Information

Totifen (ketotifen) is available in both ophthalmic (eye drop) and oral formulations, with the safety profile varying between them. All use is contraindicated in patients with a known hypersensitivity to any product component.


Adverse Reactions (Ophthalmic Use)

Adverse reactions reported in clinical studies for the ophthalmic solution were generally mild and occurred in 10% to 25% of patients. The most common reactions reported were conjunctival injection, headaches, and rhinitis (runny nose). Less common ocular effects include burning/stinging, dry eyes, eye pain, and allergic reactions. Systemic exposure following topical administration is very low.

Classification Common Adverse Reactions (10%-25%)
Ocular Conjunctival Injection, Burning/Stinging
Non-Ocular Headache, Rhinitis

Safety Considerations and Restrictions

  • Pediatric Use: Safety and effectiveness for the ophthalmic solution have not been established in children below 3 years of age.
  • Contact Lenses: Totifen ophthalmic solution contains benzalkonium chloride, a preservative that may be absorbed by soft contact lenses. Lenses must be removed before use and reinserted after at least 10 minutes. The product is not intended to treat contact lens-related irritation.
  • Pregnancy/Lactation: The ophthalmic formulation is classified as Pregnancy Category C. Caution is advised during pregnancy and breastfeeding, as animal studies demonstrated excretion into breast milk following oral administration, though systemic absorption from topical use is minimal.
  • Drug Interactions (Oral Use): The oral form may potentiate the effects of CNS depressants, including alcohol, sedatives, and hypnotics. Caution is also advised when the oral form is used concurrently with oral antidiabetic agents due to rare reports of a reversible fall in platelet count.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Totifen overdose documents serious clinical manifestations primarily across the central nervous and cardiovascular systems. Overdose presentations are characterized by significant neurological effects, including severe drowsiness, confusion, disorientation, and the potential for hyperexcitability, generalized convulsions, or reversible coma. Cardiovascular findings that may occur include an increase in heart rate (tachycardia) and abnormally low blood pressure (hypotension).

Regulators mandate immediate action when an overdose is suspected. Individuals must seek immediate medical attention or get emergency help immediately and contact a Poison Control Center right away. Urgent medical care is specifically required if severe symptoms such as passing out or difficulty breathing are present. A particular risk noted in official labeling is the observation of hyperexcitability and convulsions specifically in the pediatric population.

Treatment is defined as entirely symptomatic and supportive. No specific antidote is known or documented for this overdose. Management procedures may include monitoring of the cardiovascular system, and interventions such as gastric lavage or the administration of activated charcoal may be considered if ingestion was recent. Short-acting barbiturates or benzodiazepines are officially described for managing states of excitation or convulsions.

Therapeutic Uses of Totifen

Ketotifen is used to relieve the itching of allergic pinkeye, and is also prescribed in oral form for the prevention of asthma and various allergic symptoms.

What Totifen Treats: Main Uses and Benefits

Totifen (ketotifen) is commonly used to help with managing conditions involving episodic or fluctuating manifestations of allergic origin. Its primary uses are assisting with allergic asthma symptoms, easing persistent allergic skin conditions like chronic hives (urticaria), and reducing eye and nasal allergic discomfort. The medication helps address symptom clusters that may become intense or disruptive, such as wheezing, severe itching, and persistent eye irritation.

It is applied across domains where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states. The treatment supports the patient during difficult episodes of heightened discomfort by easing distress associated with these conditions.

“The therapy may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Supportive Management for Allergic Conditions

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Totifen?

The eligibility for using Totifen (ketotifen) is strictly governed by regulatory classifications, often differing between the oral and ophthalmic formulations.

Populations Allowed and Established

Use is officially established for adults and children aged 3 years and older for both the oral and ophthalmic forms. The oral syrup formulation may also be used in children aged 2 to 3 years.

Absolute Contraindications

The medicine is contraindicated for individuals with known hypersensitivity to any component. For the oral form, absolute non-eligibility extends to patients with known epilepsy or a history of convulsions. The oral formulation is also prohibited for use by patients taking oral antidiabetic agents and by breastfeeding mothers.

Restricted and Conditional Use

Safety and effectiveness have not been established for the ophthalmic solution in children below the age of 3 years. The oral form's use in pregnant women is restricted and should only occur if the clinical condition requires it. Furthermore, no official dosing recommendations are available from regulators for patients with renal or hepatic impairment, as specific studies in these groups are lacking.

What should I know about interactions with other medicines?

The official regulatory profile for Totifen (Ketotifen) establishes interactions based predominantly on additive pharmacodynamic effects and specific procedural constraints outlined in product labeling.

Pharmacodynamic Interactions

Co-administration with CNS Depressants (such as sedatives, hypnotics, and tranquilizers) is documented to enhance the sedative effects and increase overall central nervous system depression. This is classified as an additive pharmacodynamic risk. Alcohol (Ethanol) consumption similarly enhances these sedative outcomes. Furthermore, combining Totifen with other Anticholinergic Agents may increase their respective anticholinergic activities. No explicit pharmacokinetic or metabolic interactions involving major CYP enzymes or drug transporters are consistently listed in official labeling as requiring mandatory warnings or dose adjustments.


Procedural and Timing Constraints

Specific mandatory procedural rules apply to the ophthalmic solution: soft contact lenses must be removed prior to instillation. They may be reinserted at least 10 minutes after application, a restriction tied to the preservative Benzalkonium Chloride. When using other prescribed ophthalmic preparations, administration should be separated by at least 5 minutes to avoid dilution effects.


Population-Specific Note

A population-specific substance interaction is noted for the syrup formulation: it contains carbohydrates, which is a relevant consideration that may affect the blood sugar levels of patients with diabetes mellitus.


Connection to the overall interaction profile

Official regulatory documents define the product’s interaction structure primarily through warnings of additive effects when co-administered with other CNS depressants or anticholinergic agents. The remaining profile is structured by specific, mandatory administration-timing requirements for the ophthalmic form related to the documented interaction with contact lenses.

Mechanism of Action

Totifen (Ketotifen) exerts its pharmacological action through a dual mechanism primarily targeting the allergic inflammatory cascade. The molecule functions as a non-competitive antagonist at the Histamine H1 receptor, preventing the binding of endogenous histamine to these receptors located on various cell types, including smooth muscle and vascular endothelium. This interaction modulates the downstream effects of histamine signaling.

Simultaneously, Totifen acts as a mast cell stabilizer. It inhibits the influx of calcium ions into mast cells, which is a critical step in the cell's activation pathway. By restricting calcium influx, the molecule modulates the signal transduction necessary for mast cell degranulation. This action prevents the release of preformed and newly synthesized inflammatory mediators, such as histamine, leukotrienes, and cytokines, from the storage granules of the mast cell population. Totifen's activity also includes antagonistic effects against leukotrienes, specifically inhibiting the actions of these lipid mediators, and has been observed to suppress the accumulation and activity of eosinophils at sites of physiological response.

Dosage and Administration Information

Totifen (ketotifen) is officially utilized via two distinct administration routes: oral for systemic management and ophthalmic for localized topical use.


Official Dosing and Administration Patterns

The standard oral regimen for adults is 1 mg twice daily, administered with food in the morning and evening as a consistent procedural requirement. This dosage is foundational for maintaining the necessary systemic concentration. The oral dose may be increased to 2 mg twice daily for some individuals, or a prolonged-release formulation of 2 mg may be used once daily.

The duration pattern for systemic use requires continuous administration for a minimum of two to three months to achieve the full labeled prophylactic effect. If prolonged oral therapy is discontinued, the process must be carried out progressively over a two-to-four-week period.

For topical ophthalmic use, the dosage is uniformly one drop into the affected eye(s). This must be done twice daily, maintaining an interval of approximately 8 to 12 hours between administrations.


Population and Contextual Rules

For pediatric patients aged 3 years and older, the oral dose follows the standard adult regimen of 1 mg twice daily. However, for very young children (6 months to under 3 years), the dose is calculated based on body weight at 0.05 mg per kilogram twice daily using the oral solution.

A key administration constraint for the eye drops is the mandatory requirement to remove soft contact lenses prior to instillation, with reinsertion deferred by at least 10 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Totifen

The research base for Totifen (Ketotifen Fumarate) has explored its potential role in managing symptoms across several allergic conditions, utilizing both a topical ophthalmic form and an oral formulation. Studies have varied in design, duration, and the specific populations examined. The research is summarized here based on the findings reported in scientific literature.


Evidence for Use in Allergic Conjunctivitis (Eye Drops)

Research into the eye drop formulation primarily consists of short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time following exposure to an allergen. Key outcomes monitored were outcomes related to physical discomfort, specifically patient-reported ocular itching and investigator-assessed visual signs. Studies included adults and children (typically ge 3 years of age).

The findings describe patterns observed in these studies, which often included exploring the timing of the measured changes (a research term known as kinetics) and tracking symptom evolution over several hours, relative to the comparator solution. However, there is limited information for long-term outcomes regarding continuous use beyond one month.


Evidence for Prophylactic Control of Allergic Asthma (Oral Form)

The available research for the oral form is based on systematic reviews and meta-analyses compiling data from older RCTs. These studies monitored outcomes related to physical discomfort, specifically the frequency, severity, and duration of asthma-related symptoms in children with mild to moderate atopic asthma.

Findings describe patterns observed in the studies, which indicated measurements of symptom change and reduced reliance on bronchodilator use in some groups of children after several weeks. However, the evidence quality varies across studies, and the methodological quality of many older trials is noted as a constraint, suggesting certainty may remain low.


What is Still Uncertain About Totifen Research

Across multiple indications, comparative evidence is lacking for how Totifen compares against newer or current standard-of-care treatments. Long-term studies are not well-established for all uses, and there is limited information for long-term outcomes or durability of response beyond the defined study intervals. The research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Totifen (FAQ)


Q: How quickly does Totifen usually start working?

Studies and official information indicate that the preventive anti-allergic effect of Totifen is slow to develop. While the active ingredient reaches peak concentration in a few hours, the maximum therapeutic benefit usually requires continuous administration for 10 to 12 weeks. Therefore, consistent administration is necessary to achieve the maximum benefit reported in studies.


Q: Can Totifen affect my sleep?

Yes, according to the official product information, drowsiness and sedation are commonly reported side effects, especially when starting the therapy. Conversely, in children, central nervous system stimulation may occur, which is reported as agitation, irritability, or difficulty sleeping.

--ố

Q: Is it okay to drink coffee while taking Totifen?

Regulatory documents do not specifically mention interactions with coffee. However, because this medicine is known to cause drowsiness, any stimulant consumption should be evaluated by a healthcare professional. This evaluation helps prevent interference with the sedative effects of the medicine.


Q: Why do some people say Totifen made them feel dizzy?

Official reports list dizziness (lightheadedness) as a known side effect that may be experienced, particularly during the initial phase of treatment. This can sometimes be related to orthostatic hypotension, which is a drop in blood pressure that occurs when quickly changing from a sitting or lying position to standing.


Q: What should I do if I forget to take my Totifen dose?

Official labeling generally instructs that a missed dose may be taken when remembered, unless it is nearly time for the next dose, in which case the missed dose must be skipped. Double doses are strictly prohibited by regulatory guidelines.


Q: How long can a person safely take Totifen?

For the preventive treatment of certain allergic conditions, the medicine needs to be maintained for at least two to three months to determine if it is effective. The anti-allergic effects have been observed to persist during continuous administration for one year or longer. The appropriate duration of therapy must be determined by a healthcare provider.


Q: Is there a generic version of Totifen available?

Yes. The active ingredient in Totifen is Ketotifen Fumarate, and this substance is available as a generic drug. This means there are multiple generic products on the market, particularly in the ophthalmic (eye drop) form.


Q: Does Totifen interact with common over-the-counter cold medicines?

Official warnings advise that Totifen may interact with medications that cause drowsiness (known as CNS depressants) or those with anticholinergic effects, often found in common over-the-counter cold or allergy remedies. Combining these can lead to increased side effects such as enhanced sedation.


Q: Will I experience withdrawal symptoms if I stop taking Totifen?

The medicine is not associated with psychological or physical dependence. However, regulatory instructions require that the reduction of other existing prophylactic agents (if used for asthma) must be gradual when initiating or stopping Totifen therapy.


Q: Can older adults take Totifen safely?

Official product documents indicate that no specific evidence exists suggesting elderly patients need a different dosage or experience different side effects compared to younger adults. The determination of safety and appropriate use in this population requires a specific determination by a healthcare professional.


Q: Can Totifen cause liver or kidney problems?

Official safety information states that liver dysfunction has been reported as a rare, serious side effect. For individuals who already have existing liver or kidney impairment, specific dosing recommendations are lacking in regulatory documents, as studies have not been performed in these patient groups.


Q: What are the symptoms of an allergic reaction to Totifen?

Symptoms of a severe allergic reaction (hypersensitivity) may include developing a rash, experiencing itching, or noticing swelling of the face, tongue, or throat. Difficulty breathing or severe dizziness are also potential signs. If these symptoms occur, they are considered medical emergencies that warrant immediate professional evaluation.


Q: Can I take vitamins or supplements with Totifen?

The official labeling requires disclosure of all products—including prescription and non-prescription medications, vitamins, nutritional supplements, and herbal products—to the healthcare provider. This disclosure is necessary for your provider to check for any potential interactions.


Q: What happens if I accidentally take two doses of Totifen?

Taking more than the prescribed amount is considered an overdose, and symptoms can include confusion, blurred vision, or severe drowsiness. More serious effects may include convulsions or a fast or irregular heartbeat. Due to the seriousness of potential symptoms, medical evaluation and monitoring are necessary.


Q: What if Totifen doesn't seem to be working for me after a few weeks?

The full therapeutic benefits of this medicine are slow to develop, with maximum effectiveness taking up to 10 to 12 weeks of continuous therapy. This long onset time supports the need for consistent administration as prescribed to allow the full benefit to manifest.


Q: Is it possible for Totifen to interact with herbal remedies?

Regulatory labeling requires disclosure of all herbal products to the healthcare provider. This is to ensure that the provider can assess the potential for interaction between the herbal remedy and the active ingredient in Totifen.


Q: Is Totifen known by any other drug names?

Yes. The active ingredient is known chemically as Ketotifen Fumarate. While Totifen is a brand name, other brand names for the oral form, such as Zaditen, also exist internationally. The ophthalmic form is widely available generically under its chemical name.


Q: Can Totifen be crushed or split if it is a tablet?

Official product labeling does not always contain explicit instructions regarding crushing or splitting the tablets. The alteration of certain tablet types, such as those designed for sustained release, is generally contraindicated. Specific advice must be obtained from a pharmacist.


Q: Why is Totifen not recommended for people with certain heart conditions?

Official safety documents note that symptoms of an overdose can include a fast, pounding, or irregular heartbeat. Due to this cardiovascular risk profile, patients with pre-existing heart conditions should be medically evaluated before use.


Q: How long does Totifen stay in your system after stopping?

The drug is eliminated from the body in two phases, known as biphasic elimination. The longer elimination phase, or half-life, is documented to be approximately 21 to 22 hours in adults.


Q: What if I experience a rare side effect mentioned in the leaflet?

If any rare but severe side effect occurs, or if there is a sudden worsening of any existing symptoms, this warrants immediate professional medical evaluation. Reporting such adverse events helps maintain the regulatory safety profile of the medicine.


Q: Does Totifen cause weight gain or loss?

Official product information confirms that weight gain has been reported as a possible side effect of this medicine, although this is noted to be a less common occurrence.


Q: Can Totifen change my mood or emotional state?

Yes. Official safety information indicates that this medicine may cause central nervous system stimulation in some individuals, which can manifest as becoming irritable, nervous, or excited. These mood changes are noted to be especially likely to occur in children.


Q: Is it normal to feel a bit nauseous when first starting Totifen?

Yes, nausea is reported in the official safety profile as a known gastrointestinal side effect. Some individuals may experience this discomfort when beginning treatment.


Q: What is the shelf life of Totifen?

The expiration date of the unopened product is listed on the packaging. For the ophthalmic solution (eye drops), regulatory guidelines mandate disposal within a specific period after opening, which varies by product and preservative type.


Q: Can I drive or operate machinery while taking Totifen?

Due to the potential for side effects such as drowsiness, dizziness, or blurred vision, official advice states that activities requiring mental alertness, such as driving or operating heavy machinery, are restricted until the effect of the medicine is known.

How should Totifen be stored and disposed of?

Storage Requirements

Official regulatory documents specify that Totifen (ketotifen ophthalmic solution) must be stored at a controlled temperature range of 4 C to 25 C (39 F to 77 F). The product must not be exposed to temperatures outside this range, such as freezing or excessive heat, to maintain its stability. It is mandatory to keep the container tightly closed when not in use. For safety, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Totifen must adhere to official guidance. If a specific take-back program is unavailable, the general regulatory instruction is to mix the medicine with an undesirable substance (such as used coffee grounds) and place it in a sealed container for disposal in the household trash. Unless the product labeling explicitly advises otherwise, the medicine must not be flushed down the toilet or poured into a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Totifen found in:

A-Z Index: